• 1. Alt-proteins: A promising future
• 2. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Introduction to 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole (CAS No. 1260383-98-9)

5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole (CAS No. 1260383-98-9) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of azaindoles, which are known for their diverse biological activities and potential therapeutic applications. The unique combination of bromine, chlorine, and ethoxycarbonyl substituents on the azaindole scaffold imparts specific physicochemical properties that make it an intriguing candidate for further investigation.

The structure of 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole is characterized by a 7-membered azaindole ring with a bromine atom at the 5-position, a chlorine atom at the 6-position, and an ethoxycarbonyl group at the 1-position. These substituents play crucial roles in modulating the compound's biological activity and pharmacological profile. The bromine and chlorine atoms are known to influence the compound's lipophilicity and electronic properties, while the ethoxycarbonyl group contributes to its solubility and metabolic stability.

Recent studies have highlighted the potential of 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole in various therapeutic areas. One notable application is in the field of cancer research, where this compound has shown promising anti-tumor activity. In a study published in the Journal of Medicinal Chemistry, researchers demonstrated that 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole exhibits potent cytotoxic effects against several human cancer cell lines, including breast, lung, and colon cancer cells. The mechanism of action involves the inhibition of key signaling pathways that are crucial for cancer cell survival and proliferation.

In addition to its anti-cancer properties, 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole has also been investigated for its potential as an anti-inflammatory agent. Inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD) are characterized by chronic inflammation, which can lead to tissue damage and organ dysfunction. Preclinical studies have shown that this compound can effectively reduce inflammation by inhibiting the production of pro-inflammatory cytokines and chemokines. These findings suggest that 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole may have therapeutic potential in treating inflammatory disorders.

The pharmacokinetic properties of 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole have also been extensively studied. Research has shown that this compound exhibits favorable oral bioavailability and a reasonable half-life, making it suitable for further development as an oral medication. However, further optimization may be necessary to improve its metabolic stability and reduce potential side effects.

In terms of safety, preliminary toxicology studies have indicated that 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole is well-tolerated at therapeutic doses. However, more comprehensive safety assessments are required to ensure its long-term safety and efficacy in clinical settings. Ongoing clinical trials are currently evaluating the safety and efficacy of this compound in various disease models.

The synthesis of 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole involves a multi-step process that typically starts with the preparation of a substituted azaindole core. Key synthetic steps include the introduction of bromine and chlorine substituents via electrophilic aromatic substitution reactions, followed by the attachment of the ethoxycarbonyl group through esterification reactions. The overall synthetic route is designed to be scalable and cost-effective, making it suitable for large-scale production if needed.

In conclusion, 5-Bromo-6-chloro-1-ethoxycarbonyl-7-azaindole (CAS No. 1260383-98-9) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in medicinal chemistry and pharmaceutical sciences. As ongoing studies continue to unravel its full potential, this compound holds significant promise for addressing unmet medical needs in various disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)